Product image of Lenalidomide Ratiopharm (Lenalidomide) supplied by GNH India

Lenalidomide Ratiopharm

Active Ingredient:
Lenalidomide
Origin:
EU

Lenalidomide Ratiopharm (Lenalidomide)

Lenalidomide, the active ingredient in Lenalidomide Ratiopharm, is an immunomodulatory drug (IMiD) presented as an oral tablet for systemic use. It is indicated for the treatment of multiple myeloma, myelodysplastic syndromes with del(5q), and mantle cell lymphoma in adult patients.

GNH India supplies Lenalidomide Ratiopharm as a licensed, GDP‑compliant international pharmaceutical supplier, serving hospitals, oncology centres and pharmacies worldwide with reliable sourcing and regulatory support. Our network ensures timely delivery and adherence to local import requirements. We maintain strict quality control throughout the supply chain.

Manufacturer / TM Owner

Ratiopharm Gmbh

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Lenalidomide is used in hematologic malignancies and related disorders, targeting abnormal plasma cells and dysplastic marrow.

  • Multiple Myeloma: improves progression‑free survival and overall response when combined with dexamethasone or other agents.
  • Myelodysplastic Syndromes with del(5q): reduces transfusion dependence and induces cytogenetic remission.
  • Mantle Cell Lymphoma: used in relapsed or refractory disease to achieve disease control.

How It Works

  • Lenalidomide binds to the cereblon subunit of the CRL4‑E3 ubiquitin ligase complex, altering its substrate specificity. This leads to ubiquitination and proteasomal degradation of transcription factors such as Ikaros and Aiolos, resulting in anti‑angiogenic activity, modulation of cytokine production, and enhanced immune‑mediated tumor cell killing. It also affects the tumor microenvironment by decreasing VEGF levels and stimulating natural killer cell activity.

Side Effects

Lenalidomide may cause a range of adverse reactions, varying in frequency and severity.

Common Side Effects

  • Fatigue: persistent tiredness affecting daily activities.
  • Diarrhea: loose stools that may require hydration.
  • Nausea: mild to moderate upset stomach.
  • Rash: skin erythema or mild itching.
  • Cytopenias: reduced blood cell counts, especially neutropenia and thrombocytopenia.

Serious or Rare Side Effects

  • Venous thromboembolism: deep vein thrombosis or pulmonary embolism.
  • Severe neutropenia: increased infection risk.
  • Secondary primary malignancies: emergence of new cancers.
  • Hepatotoxicity: elevated liver enzymes or liver injury.

Precautions & Warnings

Before initiating Lenalidomide therapy, several safety considerations should be reviewed.

  • Pregnancy risk: contraindicated in pregnancy (Category X); ensure effective contraception.
  • Thromboembolic risk: assess need for prophylactic anticoagulation.
  • Renal function: dose may require adjustment in impaired kidney function.
  • Hepatic function: monitor liver enzymes in patients with liver disease.
  • Infection monitoring: watch for signs of infection due to neutropenia.
  • Store at ambient temperature: keep below 25 °C, in original packaging, protected from moisture and light.

Avoid Interactions

Lenalidomide can interact with other medicines, influencing efficacy or safety.

Major Interactions (Avoid)

  • Strong CYP3A4 inducers: may reduce lenalidomide exposure.
  • Anticoagulants (warfarin, DOACs): increased risk of bleeding when combined with lenalidomide‑induced thrombocytopenia.

Moderate Interactions (Monitor Closely)

  • Immunosuppressants (e.g., cyclosporine): may enhance hematologic toxicity.
  • Vaccines: live vaccines should be avoided during treatment.
  • NSAIDs: may increase risk of renal impairment when combined with lenalidomide.
  • Hormonal contraceptives: effectiveness may be reduced; use additional barrier methods.

Frequently Asked Questions

Lenalidomide Ratiopharm is an oral immunomodulatory agent indicated for adult patients with multiple myeloma, myelodysplastic syndromes that carry the del(5q) chromosomal abnormality, and mantle cell lymphoma, particularly in relapsed or refractory settings.

The drug binds to cereblon, a component of the CRL4‑E3 ubiquitin ligase complex, changing its substrate profile. This triggers degradation of specific transcription factors, leading to anti‑angiogenic effects, modulation of cytokine release, and enhanced immune‑mediated killing of malignant cells.

The prescribed dose of Lenalidomide Ratiopharm is determined by the treating physician based on the specific indication, patient’s renal function, prior therapies, and overall clinical status. No fixed regimen is provided here; dosing must follow the prescriber’s order.

Lenalidomide is classified as Pregnancy Category X, meaning it is contraindicated during pregnancy because of a high risk of fetal harm. It is also not recommended while breastfeeding, as it may be excreted in milk and affect the infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lenalidomide is a second‑generation immunomodulatory drug, offering greater potency and a more favorable safety profile than thalidomide, the first‑generation analogue. Compared with pomalidomide, another newer IMiD, lenalidomide is typically used earlier in therapy and has a broader label across multiple hematologic cancers.

Store the tablets at ambient temperature, preferably below 25 °C. Keep them in the original blister pack, protect from moisture and direct light, and ensure the container is tightly closed to maintain product stability.

Lenalidomide Ratiopharm is taken orally as a tablet. It should be swallowed whole with water, with or without food, according to the prescribing physician’s instructions. Patients should not crush or chew the tablet unless specifically directed.

Key serious risks include venous thromboembolism (deep‑vein thrombosis or pulmonary embolism), severe neutropenia leading to infections, secondary primary malignancies, and significant liver enzyme elevations. Prompt medical attention is required if symptoms of clotting, infection or liver dysfunction appear.

Lenalidomide should not be used by pregnant women, individuals with known hypersensitivity to the drug or its excipients, and patients with uncontrolled severe infections. Caution is also advised for those with severe renal or hepatic impairment, and the decision must be made by a qualified clinician.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Lenalidomide

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT